PORTOLA VALLEY, Calif., Oct. 19 /PRNewswire/ -- Spectros, developer and manufacturer of advanced molecular sensing and imaging devices which shed light on life-threatening diseases, announced today that it has signed exclusive distribution deals for both its T-Stat® VLS Tissue Oximeter and Sensors. The markets covered include Australia, New Zealand, The Netherlands, Belgium, Luxembourg (Benelux), Suriname, Italy, France, Spain, Portugal, Poland, Greece, Turkey, and Russia. The values of the deals were not disclosed.
Founded in 1995, Spectros develops tissue oximeters and sensors for various uses with applications in critical care, gastroenterology, colon-rectal surgery, plastic surgery, and vascular surgery. T-Stat® VLS Tissue Oximeter is an FDA-approved and CE Marking device approved for neonatal, pediatric, and adult use.
"We are proud to be working with our new partners, Endovations in Australia, Fysicon Medical Technology in the Netherlands, and A.M.I. Italia s.r.l. in Italy, who are providing the T-Stat® franchise in their respective markets in order to realize our potential," said David Benaron, CEO of Spectros. "Support of our technology is a testament to their commitment to offering their healthcare communities with innovative and life-saving solutions," commented Robert Kum, director of commercial development.
The T-Stat® franchise includes the T-Stat® VLS Tissue Oximeter, utilizing Visible Light Spectroscopy (VLS), a multi-wavelength, noninvasive, continuous, real-time monitor of absolute hemoglobin oxygen saturation. The T-Stat® Sensors allow for ischemia monitoring in various applications, including critical care (neonatal, pediatric, and adult), gastroenterology (G.I. ischemia diagnosis), colon-rectal surgery (anastomosis), plastic surgery (free flaps), and vascular surgery (AAA, TAAA, and EVAR).
Based in Australia, Endovations Pty. Ltd. is a leader in the field of critical care, respiratory, anesthesia, and surgical applications. Endovations will distributor the T-Stat® VLS Tissue Oximeter and Sensors to the Australian and New Zealand markets.
Based in the Netherlands, Fysicon Medical Technology is a leader in the field of cardiology. The company will distribute the T-Stat® VLS Tissue Oximeter and Sensors to the Dutch, Belgium, and Luxembourgian (Benelux), and Suriname markets.
Based in Italy, A.M.I. Italia s.r.l. is a leader in the patient monitoring market. A.M.I. will distribute the T-Stat® VLS Tissue Oximeter and Sensors in Italy, France, Spain, Portugal, Poland, Greece, Turkey, and Russia.
Spectros markets advanced molecular sensing and imaging devices that shed light on ischemia and cancer. The company's lead product, the T-Stat Tissue Oximeter, was the first medical device FDA approved as sensitive to ischemia, an insufficient blood flow to tissue. T-Stat is the only commercially available tissue oximeter that utilizes state-of-the-art visible light spectroscopy (VLS) technology. In clinical use, T-Stat is a real-time, absolute, non-invasive, and continuous tissue monitor that analyzes 260 wavelengths of light, far more than the 2-4 wavelengths used in other monitors for superior accuracy. Spectros is also developing molecular diagnostic tools for breast and prostate cancer currently in phase I/II clinical trials supported by the National Cancer Institute. Spectros is a venture-supported private concern and markets its products in the U.S. and internationally. For further information, contact Elizabeth van Thillo, Marketing, Spectros Corporation, at firstname.lastname@example.org or 650/529.2865